News | December 17, 2006

FDA Says Yes to Stroke Device Study

The FDA has given CoAxia Inc. approval to move forward on a safety and feasibility study for the NeuroFlo perfusion augmentation therapy in ischemic stroke patients who present for treatment as late as 24 hours after stroke onset. Perhaps the first interventional device trial approved for this patient population, the study will enroll up to 25 patients and the results will determine future expansion to a pivotal study in late presenting stroke patients.

"This study represents another important step in applying medical devices to the treatment of acute stroke,” said Souvik Sen, M.D., director of the Stroke Service at the University of North Carolina and a co-author of the study. “There are no treatments currently approved to treat stroke patients in this eight- to 24-hour time window after symptom onset. If NeuroFlo can safely treat the large number of patients who present in this time window, it will have a major impact in stroke treatment."

The SafeFlo24 trial will evaluate the safety of the NeuroFlo perfusion augmentation catheter in stroke patients presenting for treatment between eight and 24 hours after last known to be normal. The study’s other co-authors are Lee Schwamm, M.D. from Massachusetts General Hospital, Maxim Hammer, M.D. from University of Pittsburgh Medical Center and David Liebeskind, M.D. from UCLA Medical Center. In addition to these four centers, the University of Rochester, New York, the University of Alberta, Edmonton and the University of Calgary, Calgary, will participate in the study. CoAxia expects patient enrollment to begin in the first quarter of 2007.

For more information visit

Related Content

PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.
German Workshop Highlights Possibilities of Perfusion MRI
News | Stroke| July 03, 2017
When diagnosing strokes and heart diseases or looking at tumors, perfusion magnetic resonance imaging (MRI) offers a...
Stroke History Higher in Asymptomatic Versus Symptomatic Atrial Fibrillation Patients
News | Stroke| June 28, 2017
Newly diagnosed asymptomatic atrial fibrillation patients have a higher rate of previous stroke than those with...
Analysis Shows Increased Risk of Early Stroke with New-Onset Atrial Fibrillation Post-TAVR, SCAI 2017 late-breaking clinical trial
News | Stroke| May 12, 2017
More than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) were observed to have atrial...
3-D-printed Model of Stenotic Intracranial Artery Enables Vessel-Wall MRI Standardization
News | 3-D Printing| April 18, 2017
A collaboration between stroke neurologists at the Medical University of South Carolina (MUSC) and bioengineers at the...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
hyperbaric oxygen treatment, HBOT, stroke, David Steenblock D.O.

Image courtesy of David Steenblock, D.O.

News | Stroke| April 06, 2017
David Steenblock, D.O., an osteopathic physician based in San Clemente, Calif., recently discussed his use of...
marijuana use, increased risk, stroke, heart failure, ACC 2017 study
News | Stroke| March 15, 2017
Using marijuana raises the risk of stroke and heart failure even after accounting for demographic factors, other health...
warfarin, anticoagulation therapy, atrial fibrillation patients, Duke Clinical Research Institute study, stroke
News | Antiplatelet and Anticoagulation Therapies| March 14, 2017
More than 80 percent of stroke patients with a history of atrial fibrillation either received not enough or no...
Overlay Init